Zimocefox 500 mg - 10 F.C. Tablets

Antibiotic, belongs to Cephalosporin (Second Generation) used in the treatment of acute otitis media, pneumonia, streptococcal pharyngitis, urinary tract infection and prophylaxis or treatment of bite wound infection.

-Suspension: Administer with food. Shake well before use. -Tablet: May administer with or without food. -Intramuscular injection: Inject deep IM into large muscle mass. -Intravenous injection: Inject direct IV over 3 to 5 minutes. Infuse intermittent infusion over 15 to 30 minutes. -Pediatric dosing: -General dosing for the susceptible infection: infants, children, and adolescents: Mild to moderate infection: Oral: 20 to 30 mg/kg/day divided twice daily; maximum dose: 500 mg/dose, intramuscular or intravenous injections: 75 to 100 mg/kg/day divided in 3 doses; maximum dose: 1,500 mg/dose. While in case of severe infection: intramuscular or intravenous injections: 100 to 200 mg/kg/day divided in 3 to 4 doses; maximum dose: 1,500 mg/dose. -Acute otitis media: Infants ≥3 months and children: Oral suspension: 15 mg/kg/dose twice daily for 10 days; maximum dose: 500 mg/dose. -Pharyngitis/tonsillitis: Infants ≥3 months and children: Oral suspension: 10 mg/kg/dose twice daily for 10 days; maximum dose: 250 mg/dose. while the dose for adolescents is: Oral tablets: 250 mg twice daily for 10 days. -Sinusitis: Infants ≥3 months and children: Oral suspension: 15 mg/kg/dose twice daily for 10 days; maximum dose: 500 mg/dose. Adolescents: Oral tablet: 250 mg twice daily for 10 days. -Uncomplicated urinary tract infection: Infants and children 2 to 24 months: Oral suspension: 10 to 15 mg/kg/dose twice daily. While for children >24 months: Moderate to severe disease (possible pyelonephritis): Oral suspension: 20 to 30 mg/kg/day divided twice daily; maximum dose: 500 mg/dose. While for adolescents: Oral tablet: 250 mg twice daily for 7 to 10 days. -Pneumonia: Infants and children: IV: 35 to 50 mg/kg/dose 3 times daily; maximum dose: 2,000 mg/dose.

Diarrhea, local thrombophlebitis, diaper rash, increased lactate dehydrogenase, nausea and vomiting, unpleasant taste, vaginitis, decreased hematocrit, decreased hemoglobin, eosinophilia, increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased serum aspartate aminotransferase.

-Should not be given to patients suffering from hypersensitivity to cefuroxime. -Prolonged use may result in fungal or bacterial superinfection. -Use with caution in patients with a history of colitis. -Use with caution in patients with renal impairment. -Use with caution in patients with a history of seizure disorder. -Incase of over dose be ready to tell or show what was taken, how much and when it happened, and seek immediate medical attention. For additional information call us on 16676. Always tell your physician your detailed medical history.

Store at room temperature.

-Antacids: May decrease the serum concentration of Cefuroxime. -BCG Vaccine: Antibiotics may diminish the therapeutic effect of BCG Vaccine. -Histamine H2 Receptor Antagonists: May decrease the absorption of Cefuroxime. -Inhibitors of the Proton Pump (PPIs and PCABs): May decrease the absorption of Cefuroxime. -Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. -Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists.

-Cefuroxime crosses the placenta. An increased risk of major birth defects or other adverse fetal or maternal outcomes has generally not been observed following maternal use of cephalosporin antibiotics, including cefuroxime. Cefuroxime is one of the antibiotics effective for prophylactic use prior to cesarean delivery. -Cefuroxime is present in breast milk. The relative infant dose (RID) of cefuroxime is 0.5%, in general, breastfeeding is considered acceptable when the RID is <10%. Diarrhea has been reported in breastfeeding infants exposed to cefuroxime. In general, antibiotics that are present in breast milk may cause non-dose-related modification of bowel flora, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.

BIOMED PHARMACEUTICALS